HUYA Bioscience International has appointed Alain Rolland as executive vice president and chief scientific officer.
He has more than 25 years of international leadership experience in biopharma, including positions at Galderma and Valentis. The company has also appointed John Sharp as chief financial officer and Clem Gingras as chief technology officer and chief operating officer for Asia.
Mr Sharp has more than 20 years’ experience in finance, with a biopharma focus. Mr Gingras has 18 years of management and operational experience with international brands.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze